Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group
Gabriella Scarlatti(Istituti di Ricovero e Cura a Carattere Scientifico), Terri Wrin, Hanneke Schuitemaker(Johnson & Johnson (Israel)), Marianne Jansson(Lund University), Lynn Morris(National Health Laboratory Service), Mauro Malnati(Vita-Salute San Raffaele University), José Alcamı́(Apple (Israel)), Quentin J. Sattentau(University of Oxford), Vera Bongertz(Faculdades Oswaldo Cruz), Christiane Moog(Inserm), Alan Heath(Iziko Museums of South Africa), Meghna Ramaswamy(National Institute for Biological Standards and Control), Saladin Osmanov, D. C. Montefiori, Éva Mária Fenyõ, H. Holmes(National Institute for Biological Standards and Control), Lucia Lopalco(Vita-Salute San Raffaele University), Leo Heyndrickx, VR Polonis
Lund University Publications (Lund University)
January 1, 2009
Cited by 1
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
|Proceedings of the National Academy of Sciences|2003|1.2k
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule
|Journal of Virology|1992|768
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression
|Nature Medicine|1997|635
HIV-1 Cell to Cell Transfer across an Env-induced, Actin-dependent Synapse
|The Journal of Experimental Medicine|2004|609